Novo Nordisk

NVO

Market cap $252B

Novo Nordisk A/S NYSE: NVO recently announced plans to acquire Akero Therapeutics. The deal, which is valued at around $4.7 billion, is scheduled to close early in 2026.

Biotech breakthroughs are reshaping the pharmaceutical landscape, sparking lucrative deals and redefining the future of rare disease treatment. Omeros Corporation (NASDAQ:OMER) stock is rallying on Wednesday, with a session volume of 89.21 million versus the average volume of 1.11 million, as per data from Benzinga Pro.

Big Pharma reignites dealmaking as Pfizer, Novo Nordisk and Roche target obesity and metabolic diseases in a high-stakes 2025 M&A surge.

Drugmaker Novo Nordisk has begun a round of layoffs in its most important market, the United States, with affected staff set to be notified between this week and next, according to an email and two sources familiar with the matter.

Under the agreement, Novo Nordisk will be granted exclusive global rights to develop and commercialize zaltenibart.

Danish drugmaker Novo Nordisk and Omeros have signed a licensing deal worth up to $2.1 billion for the U.S.-based company's experimental drug, which is being developed for rare blood and kidney disorders, they said on Wednesday.

Danish pharmaceutical giant Novo Nordisk (NVO -1.47%) has endured a significant decline in stock price, falling over 50% in the past year. The stock's miserable performance is particularly jarring, considering the pharmaceutical company is one of the leading players in the rapidly growing obesity drug market, which industry experts anticipate will explode to $150 billion in global sales by 2035, up from just $15 billion last year.

Romel Amineh is one of a fast-growing group of Novo Nordisk workers in Denmark laid off as the drugmaker battles to cut costs and revive its fortunes in a fiercely competitive global obesity drug market. They call themselves the "Club 5,000".

Novo Nordisk (NVO) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

One of the great things about equity markets is that excellent stocks can be had at almost any price, making them accessible to most people. Even with $100, it's possible to find outstanding, growth-oriented companies to invest in.